Medicines Co.’s Angiox Heart Drug Wins U.K. Cost Agency Approval
Medicines Co.’s Angiox can be given to adults who suffer a form of heart attack known as an ST- segment elevation myocardial infarction, or STEMI, the U.K.’s medical-cost regulator said.
Angiox can be given with aspirin and clopidogrel to STEMI patients who are undergoing primary percutaneous coronary intervention, the National Institute for Health and Clinical Excellence said in guidelines published today. The agency, also known as NICE, rules on which treatments the U.K.’s National Health Service will fund.
To contact the reporter on this story: Andrea Gerlin in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com